KRYS - Krystal Bio completes patient enrollment in GEM-3 trial of B-VEC for dystrophic epidermolysis bullosa

Krystal Biotech (KRYS), has completed enrollment in the GEM-3 study of B-VEC for dystrophic epidermolysis bullosa ((DEB)).Top-line results are expected in Q4. The trial enrolled 31 patients ranging in ages from one year to 44 years old.In each patient, a primary wound pair(s) was identified by the investigator; one wound was randomized to receive a weekly topical application of B-VEC and the other to placebo. Also, additional wounds (secondary wounds) may be selected to be treated with B-VEC giving the treating physicians and patients flexibility to treat a larger number of wounds. Subjects will return to the clinical site 30 days following the last dosing visit (week 24) for safety evaluation, and will subsequently have the option to roll into the Open Label Extension Study.

For further details see:

Krystal Bio completes patient enrollment in GEM-3 trial of B-VEC for dystrophic epidermolysis bullosa